News & Updates

In patients with the coronavirus disease 2019 (COVID-19), hypertension aggravates the risk of cardiac injury and severe disease phenotype, a recent study has found.

The pan-sarbecovirus monoclonal antibody sotrovimab appears to reduce the risk of COVID-19 disease progression in high-risk patients, according to interim results of the phase III COMET-ICE* trial.

For three decades, hypertension-related cardiovascular disease (CVD) burden in young adults has substantially rose, with spatiotemporal and sexual heterogeneity, according to a study. Middle-income countries bear the heaviest burden, particularly men.